Publicaciones en colaboración con investigadores/as de Tel Aviv University (36)

2024

  1. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  2. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

  3. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  4. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)

    Antibiotics, Vol. 12, Núm. 9

  2. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations (Scientific Reports, (2023), 13, 1, (17235), 10.1038/s41598-023-43287-4)

    Scientific Reports

  3. Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey

    European Archives of Oto-Rhino-Laryngology, Vol. 280, Núm. 5, pp. 2309-2316

  4. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

    Scientific Reports, Vol. 13, Núm. 1

  5. Diminishing benefits of urban living for children and adolescents’ growth and development

    Nature, Vol. 615, Núm. 7954, pp. 874-883

  6. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

    Movement Disorders, Vol. 38, Núm. 2, pp. 286-303

  7. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

  8. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  9. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  10. International palate surgery questionnaire

    Sleep and Breathing, Vol. 27, Núm. 2, pp. 569-590

2022

  1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  2. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  3. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

  4. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

    Circulation, Vol. 146, Núm. 20, pp. 1507-1517

  5. Refining the mutational spectrum and gene-phenotype correlates in pontocerebellar hypoplasia: Results of a multicentric study

    Journal of Medical Genetics, Vol. 59, Núm. 4, pp. 399-409

  6. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 21